Rigel Pharmaceuticals To Present Final GAVRETO Phase 1/2 ARROW Study Data In RET Fusion-Positive NSCLC And Solid Tumors, Along With Supportive REZLIDHIA Data For mIDH1 R/R AML At ASCO And EHA 2025 Conferences

Author: Benzinga Newsdesk | May 22, 2025 05:36pm

• Final data from the GAVRETO® (pralsetinib) Phase 1/2 ARROW study in RET fusion-positive NSCLC and other solid tumors  
• Supportive data for REZLIDHIA® (olutasidenib) utilization in patients with mIDH1 R/R AML

SOUTH SAN FRANCISCO, Calif., May 22, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced seven upcoming poster presentations at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) 2025 Congress. The ASCO Annual Meeting is being held in Chicago, Illinois and virtually from May 30 to June 3, 2025. The EHA2025 Congress is being held in Milan, Italy and virtually from June 12 to June 15, 2025.

Posted In: RIGL